Anticoagulant drugs that are currently used to prevent and/or treat thrombosis have some limitations that hinder their ability to meet specific clinical requirements. While these drugs effectively reduce the rates of thrombotic events, they simultaneously increase the risk of bleeding. Moreover, their risk-to-benefit balance is problematic in some patients, such as those with severe chronic kidney disease or those at high bleeding risk. A novel anticoagulation method, FXI inhibition has emerged as a promising alternative. It demonstrates a strong rationale for the prevention and treatment of venous thromboembolism and the potential fulfillment of unmet clinical needs in the cardiovascular field. A number of FXI inhibitors are currently undergoing clinical investigation. The objective of this review is to provide an overview of early results of research on FXI inhibitors in the cardiovascular setting, offering valuable insights into their potential role in shaping the future of anticoagulation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.blre.2023.101119 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Systematic Review of Safety and Efficacy of Factor XI/XIa Inhibitors in Patients With ESKD on Hemodialysis.
Kidney Int Rep
January 2025
Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Introduction: Factor XI/XIa (FXI/XIa) has emerged as a potential target for antithrombotic therapy, driven by preclinical evidence showing the role of FXI/XIa inhibition for preventing thrombosis without impeding hemostasis. This is particularly promising for patients at high risk of both thromboembolic events and bleeding, such as patients with end-stage kidney disease (ESKD) on hemodialysis (HD).
Methods: We systematically searched Embase, MEDLINE, and ClinicalTrials.
Diagnosis, treatment, surgical practices and review of the literature in rare coagulation factor deficiencies.
Ital J Pediatr
January 2025
Pediatric Hematology and Oncology, SBU Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.
Background: Rare bleeding disorders (RBDs) include fibrinogen (Factor I), prothrombin (Factor II), Factor V(FV), combined Factor V and Factor VIII, Factor VII, Factor X, Factor XI, Factor XII, and Factor XIII deficiencies. This group accounts for 3-5% of all factor deficiencies. Different symptoms may occur, ranging from mild or moderate bleeding to serious and life-threatening bleeding, which may not be related to the factor level.
View Article and Find Full Text PDFNew targets for antithrombotic medications: seeking to decouple thrombosis from hemostasis.
J Thromb Haemost
December 2024
Division of Cardiovascular Medicine, Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan, USA. Electronic address:
Arterial and venous thromboses are the leading causes of morbidity and mortality worldwide. Numerous antithrombotic agents are currently available with antiplatelet, thrombolytic/fibrinolytic, and anticoagulant activity. However, all the currently available antithrombotic agents carry a risk of bleeding that often prevents their use.
View Article and Find Full Text PDFAssociation of Coagulation Factor XI Level With Cardiovascular Events and Cardiac Function in Community-Dwelling Adults: From ARIC and CHS.
Circulation
November 2024
Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis. (Y.J., M.J.Z., J.V-H., L.Y.C.).
Article Synopsis
- Coagulation factor XI (FXI) inhibitors show potential as new anticoagulants but may worsen heart failure and diastolic dysfunction according to an animal study.
- In the ARIC study, involving 4,471 older participants, researchers found that lower plasma FXI levels were linked to a higher incidence of heart failure over a median follow-up of 9 years, especially in those aged 75 and older.
- The study also noted that while lower FXI levels were associated with increased prevalence of diastolic dysfunction, they correlated with a higher likelihood of atrial fibrillation at the baseline, but not with new cases of atrial fibrillation during the follow-up.
Factor XI and XIa inhibition: a new approach to anticoagulant therapy.
Br J Cardiol
May 2024
Professor of Cardiology Cardiovascular Research Unit, Clinical Research Facility, Northern General Hospital, Sheffield, S5 7AU.
Factor (F) XI or XIa inhibition has Fattracted interest due to the protection from thrombotic events and minimal bleeding tendency observed in FXI-deficient individuals. The prospect of uncoupling the management of thrombosis from the bleeding risk inadvertently associated with current therapy inspired the development of agents directed towards this step in the coagulation process. This review describes the physiological rationale behind FXI/FXIa inhibition and the pharmacological properties of existing FXI/FXIa inhibitors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!